Treatment-resistant depression responds better to esketamine with SNRI than SSRI, study finds

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of disability and low quality of life. One in every three people suffering from MDD also has to deal with treatment-resistant depression (TRD), a condition where patients do not respond to at least two antidepressant trials.

Leave A Comment

Your email address will not be published. Required fields are marked *